QuidelOrtho Corporation
0A55.L
London Stock Exchange13.56
USD
-29.94
- -
QuidelOrtho Corporation
0A55.L
(London Stock Exchange)
Recent
price
13.56
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- QuidelOrtho Corporation QuidelOrtho Corporation develops, manufactures and markets in vitro diagnostic technologies and solutions for point-of-care settings, clinical laboratories and transfusion medicine worldwide. The company offers a comprehensive portfolio of products including visually-read lateral flow tests for infectious diseases and reproductive health; direct fluorescent antibody tests for infectious disease and virology; micro-titer products focused on bone and complement pathways; fluorescent immunoassay systems such as SOFIA 2 Analyzer; molecular diagnostics like LYRA real-time PCR assays and the former Savanna platform; immunodiagnostics and clinical chemistry systems including VITROS systems; donor screening systems such as Ortho Summit, VERSEIA and VITROS; pre-transfusion testing analyzers like ORTHO VISION Swift and ORTHO VISION Swift Max with ORTHO CONNECT software; and services including Ortho Care informatics. QuidelOrtho Corporation operates in North America, Europe, the Middle East, Africa, China and other international markets, serving customers in 143 countries including hospitals, clinical labs, blood banks and point-of-care facilities; it was founded in 1979 as Hybritech in San Diego, California, where it maintains headquarters. Recent strategic developments include the planned full acquisition of LEX Diagnostics for approximately $100 million pending FDA 510(k) clearance expected in late 2025 or early 2026 to bolster point-of-care molecular diagnostics; discontinuation of the Savanna platform to reallocate resources; addition of high-sensitivity Troponin assays to the VITROS platform; successful debt refinancing in third-quarter 2025 to enhance financial flexibility; and launch of multiplex respiratory tests such as QUICKVUE Influenza + SARS amid a shift from COVID-19 revenue dependency, with over $140 million in cost savings achieved.